SCHEMBL19181752

SCHEMBL19181752

CC(O)(c1cc(Cl)c(NC(=O)Cc2ccc(F)cc2)c(Cl)c1)C(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.48
KDM4E B2RXH2 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA9 Q16790 1/20 0.46
ALDH1A1 P00352 3/20 0.45
HPGD P15428 1/20 0.45
CACNA1H O95180 1/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
ANO1 Q5XXA6 1/20 0.43
MAPK1 P28482 2/20 0.43
ATM Q13315 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
RORC P51449 1/20 0.42
KCNJ6 P48051 1/20 0.41
KCNJ5 P48544 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19180943 0.90 NLRP3 (0.52) SMN1; SMN2ANO1RORCKCNJ5KCNJ3
SCHEMBL19179625 0.88 P2RX7 (0.46) HPGDNPC1RAB9ARORCHSD11B1
SCHEMBL19288855 0.85 GAA (0.43) GAAKDM4ESMN1; SMN2CA12CA1
SCHEMBL19179851 0.83 RAB9A (0.51) GAASMN1; SMN2ALDH1A1HPGDNPC1
SCHEMBL19179565 0.79 L3MBTL1 (0.57) GAASMN1; SMN2HPGDNPC1RAB9A
SCHEMBL19181907 0.78 MCHR1 (0.47)
SCHEMBL19181906 0.78 L3MBTL1 (0.47) GAASMN1; SMN2ALDH1A1NPC1RAB9A
SCHEMBL3603325 0.73 CA12 (0.52) GAAKDM4ESMN1; SMN2CA12CA1
SCHEMBL19179705 0.73 MTOR (0.52) SMN1; SMN2CA1CA2CA9
SCHEMBL19179849 0.73 NPC1 (0.51) GAASMN1; SMN2CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3210969-B1 KCNQ2-5 CHANNEL ACTIVATOR ONO PHARMACEUTICAL CO (JP) 2021-04-28 EP disclosed
CN-107108485-B KCNQ 2-5 channel activator 小野药品工业株式会社 2020-06-12 CN disclosed
US-10676438-B2 KCNQ2-5 channel activator ONO PHARMACEUTICAL CO., LTD. (JP) 2020-06-09 US disclosed
US-10676438-B2 KCNQ2-5 channel activator ONO PHARMACEUTICAL CO., LTD. (JP) 2020-06-09 US disclosed
US-20200157050-A1 KCNQ2-5 CHANNEL ACTIVATOR ONO PHARMACEUTICAL CO., LTD. (JP) 2020-05-21 US disclosed
US-20200157050-A1 KCNQ2-5 CHANNEL ACTIVATOR ONO PHARMACEUTICAL CO., LTD. (JP) 2020-05-21 US disclosed
US-10570093-B2 2020-02-25 US disclosed
US-10570093-B2 2020-02-25 US disclosed
US-10196358-B2 KCNQ2-5 channel activator ONO PHARMACEUTICAL CO., LTD. (JP) 2019-02-05 US disclosed
US-10196358-B2 KCNQ2-5 channel activator ONO PHARMACEUTICAL CO., LTD. (JP) 2019-02-05 US disclosed
US-20170334855-A1 KCNQ2-5 CHANNEL ACTIVATOR ONO PHARMACEUTICAL CO., LTD. (JP) 2017-11-23 US disclosed
US-20170334855-A1 KCNQ2-5 CHANNEL ACTIVATOR ONO PHARMACEUTICAL CO., LTD. (JP) 2017-11-23 US disclosed
US-20170334855-A1 KCNQ2-5 CHANNEL ACTIVATOR ONO PHARMACEUTICAL CO., LTD. (JP) 2017-11-23 US disclosed
US-9809544-B2 KCNQ2-5 channel activator ONO PHARMACEUTICAL CO., LTD. (JP) 2017-11-07 US disclosed
US-9809544-B2 KCNQ2-5 channel activator ONO PHARMACEUTICAL CO., LTD. (JP) 2017-11-07 US disclosed
US-9809544-B2 KCNQ2-5 channel activator ONO PHARMACEUTICAL CO., LTD. (JP) 2017-11-07 US disclosed
EP-3210969-A1 KCNQ2-5 CHANNEL ACTIVATOR ONO Pharmaceutical Co., Ltd. (JP) 2017-08-30 EP disclosed
US-20170217888-A1 KCNQ2-5 CHANNEL ACTIVATOR ONO PHARMACEUTICAL CO., LTD (JP) 2017-08-03 US disclosed
US-20170217888-A1 KCNQ2-5 CHANNEL ACTIVATOR ONO PHARMACEUTICAL CO., LTD (JP) 2017-08-03 US disclosed
US-20170217888-A1 KCNQ2-5 CHANNEL ACTIVATOR ONO PHARMACEUTICAL CO., LTD (JP) 2017-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10570093-B2 KCNQ5, KCNQ2, KCNQ1 GAA 2225/4885KDM4E 1179/4885SMN1; SMN2 929/4885
US-20170334855-A1 KCNQ2-5 CHANNEL ACTIVATOR KCNQ5, KCNQ2, KCNQ1 GAA 1713/4885KDM4E 879/4885SMN1; SMN2 1885/4885
US-20170217888-A1 KCNQ2-5 CHANNEL ACTIVATOR KCNQ5, KCNQ2, KCNQ1 GAA 1713/4885KDM4E 879/4885SMN1; SMN2 1885/4885
US-20200157050-A1 KCNQ2-5 CHANNEL ACTIVATOR KCNQ5, KCNQ2, KCNQ1 GAA 1713/4885KDM4E 879/4885SMN1; SMN2 1885/4885
US-10676438-B2 KCNQ2-5 channel activator KCNQ5, KCNQ2, KCNQ1 GAA 1713/4885KDM4E 879/4885SMN1; SMN2 1885/4885
US-10196358-B2 KCNQ2-5 channel activator KCNQ5, KCNQ2, KCNQ1 GAA 1713/4885KDM4E 879/4885SMN1; SMN2 1885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.